 SEATTLE, WA and VANCOUVER, BC ACCESSWIRE May 24, 2021 Achieve Life Sciences, Inc. NASDAQ:ACHV, a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock offered in the public offering. 